Treatment Strategies Used in Treating Myelofibrosis: State of the Art

Treatment Strategies Used in Treating Myelofibrosis: State of the Art

Background: Current drug therapy for myelofibrosis does not alter the natural course of the disease or prolong survival, and allogeneic stem cell transplantation is the only curative treatment modality. For over a decade, the Janus kinase (JAK) inhibitor ruxolitinib has been the standard of care. Mo...

Full description

Saved in:
Bibliographic Details
Main Authors: Massimo Martino, Martina Pitea, Annalisa Sgarlata, Ilaria Maria Delfino, Francesca Cogliandro, Anna Scopelliti, Violetta Marafioti, Simona Polimeni, Gaetana Porto, Giorgia Policastro, Giovanna Utano, Maria Pellicano, Giovanni Leanza, Caterina Alati
Format: Article
Language:English
Published: MDPI AG 2024-10-01
Series:Hematology Reports
Subjects:
myelofibrosis
JAK inhibitors
ruxolitinib
fedratinib
pacritinib
momelotinib
Online Access:https://www.mdpi.com/2038-8330/16/4/67
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.mdpi.com/2038-8330/16/4/67

Similar Items